公开(公告)号：US11944627B2

公开(公告)日：2024-04-02

申请号：US16494556

申请日：2018-03-22

申请人： KURA ONCOLOGY, INC.

发明人： Francis Burrows ,  Linda V. Kessler ,  Liansheng Li ,  Pingda Ren ,  Yi Wang ,  Tao Wu ,  Jingchuan Zhang

IPC分类号： A61K31/519 ,  A61K31/44 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/505 ,  A61K31/5377 ,  A61P35/02

CPC分类号： A61K31/519 ,  A61K31/44 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/505 ,  A61K31/5377 ,  A61P35/02

摘要： The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.

公开(公告)号：US10246464B2

公开(公告)日：2019-04-02

申请号：US15509989

申请日：2015-09-08

申请人： The Regents of the University of Michigan ,  Kura Oncology, Inc

发明人： Jolanta Grembecka ,  Tomasz Cierpicki ,  Dmitry Borkin ,  Jonathan Pollock ,  Hongzhi Miao ,  Duxin Sun ,  Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu

IPC分类号： C07D495/04 ,  C07D519/00 ,  C07F9/53 ,  C07F9/6558

摘要： The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.

公开(公告)号：US20180327414A1

公开(公告)日：2018-11-15

申请号：US16014996

申请日：2018-06-21

申请人： Kura Oncology, Inc. ,  The Regents of The University of Michigan

发明人： Jolanta Grembecka ,  Tomasz Cierpicki ,  Dmitry Borkin ,  Jonathan Pollock ,  Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu ,  Szymon Klossowski

IPC分类号： C07D487/04 ,  C07D519/00 ,  C07D513/04 ,  C07D498/04 ,  C07D473/34 ,  C07D491/048 ,  C07D495/04

CPC分类号： C07D487/04 ,  C07D473/34 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

公开(公告)号：US20180105531A1

公开(公告)日：2018-04-19

申请号：US15829604

申请日：2017-12-01

申请人： Kura Oncology, Inc. ,  The Regents of The University of Michigan

发明人： Jolanta Grembecka ,  Tomasz Cierpicki ,  Dmitry Borkin ,  Jonathan Pollock ,  Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu ,  Szymon Klossowski

IPC分类号： C07D487/04 ,  C07D473/34 ,  C07D495/04 ,  C07D498/04 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D473/34 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

公开(公告)号：US09624228B2

公开(公告)日：2017-04-18

申请号：US15026581

申请日：2014-10-03

申请人： KURA ONCOLOGY, INC.

发明人： Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu

IPC分类号： C07D487/04 ,  A61K31/4439 ,  A61K31/513 ,  C07D471/04 ,  A61K9/00 ,  A61K31/4745 ,  A61K31/5377 ,  A61K31/5517 ,  A61K45/06 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K9/0053 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/5517 ,  A61K45/06 ,  A61P35/00 ,  C07B59/002 ,  C07B2200/05 ,  C07D471/04 ,  C07D519/00

摘要： The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.

公开(公告)号：USRE49687E1

公开(公告)日：2023-10-10

申请号：US17165794

申请日：2021-02-02

申请人： The Regents of The University of Michigan ,  Kura Oncology, Inc.

发明人： Jolanta Grembecka ,  Tomasz Cierpicki ,  Dmitry Borkin ,  Jonathan Pollock ,  Hongzhi Miao ,  Duxin Sun ,  Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu

IPC分类号： C07D495/04 ,  C07D519/00 ,  C07F9/53 ,  C07F9/6558

CPC分类号： C07D495/04 ,  C07D519/00 ,  C07F9/5325 ,  C07F9/65583

摘要： The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.

公开(公告)号：US11555041B2

公开(公告)日：2023-01-17

申请号：US16927844

申请日：2020-07-13

申请人： Kura Oncology, Inc. ,  The Regents of The University of Michigan

发明人： Tao Wu ,  Liansheng Li ,  Yi Wang ,  Pingda Ren ,  Jolanta Grembecka ,  Tomasz Cierpicki ,  Szymon Klossowski ,  Jonathan Pollock ,  Dmitry Borkin

IPC分类号： C07D495/04 ,  A61K31/445 ,  A61P35/02

摘要： The present disclosure provides compounds of Formula (I-A) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

公开(公告)号：US10588907B2

公开(公告)日：2020-03-17

申请号：US15578837

申请日：2016-06-03

申请人： KURA ONCOLOGY, INC. ,  THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Jolanta Grembecka ,  Tomasz Cierpicki ,  Dmitry Borkin ,  Jonathan Pollock ,  Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu

IPC分类号： C07D471/04 ,  C07D401/14 ,  A61K31/519 ,  A61P35/02 ,  A61P3/10 ,  A61K31/5377 ,  A61K31/541

摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

公开(公告)号：US10174041B2

公开(公告)日：2019-01-08

申请号：US16014996

申请日：2018-06-21

申请人： Kura Oncology, Inc. ,  The Regents of The University of Michigan

发明人： Jolanta Grembecka ,  Tomasz Cierpicki ,  Dmitry Borkin ,  Jonathan Pollock ,  Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu ,  Szymon Klossowski

IPC分类号： C07D487/04 ,  C07D519/00 ,  C07D513/04 ,  C07D498/04 ,  C07D495/04 ,  C07D491/048 ,  C07D473/34

摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

公开(公告)号：US11542248B2

公开(公告)日：2023-01-03

申请号：US16619423

申请日：2018-06-07

申请人： KURA ONCOLOGY, INC. ,  THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Liansheng Li ,  Tao Wu ,  Jun Feng ,  Pingda Ren ,  Yi Liu ,  Jolanta Grembecka ,  Tomasz Cierpicki ,  Dmitry Borkin ,  Jonathan Pollock

IPC分类号： C07D401/14 ,  A61P35/00 ,  C07D207/32 ,  C07D413/14 ,  C07D417/14 ,  C07K14/47 ,  A61K9/00 ,  A61K38/00

摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.